Trials / Completed
CompletedNCT04809220
A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes
A Randomized, Double-Blind, Parallel Arm Study of the Efficacy and Safety of Two Doses of Dulaglutide in Combination With a Single Oral Antihyperglycemic Medication or as Monotherapy in Japanese Patients With Type 2 Diabetes Mellitus (AWARD-JPN: Assessment of Weekly Administration of LY2189265 in Diabetes - JAPAN)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 591 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of 2 doses of dulaglutide in Japanese participants with type 2 diabetes. The study duration is approximately 58 weeks.
Conditions
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Glucose Metabolism Disorders
- Metabolic Disease
- Endocrine System Diseases
- Hypoglycemic Agents
- Type 2 Diabetes Mellitus (T2DM)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dulaglutide | Administered SC |
| DRUG | Oral antihyperglycemics | Administered orally |
Timeline
- Start date
- 2021-04-13
- Primary completion
- 2022-10-01
- Completion
- 2023-04-26
- First posted
- 2021-03-22
- Last updated
- 2024-05-22
- Results posted
- 2023-09-21
Locations
44 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04809220. Inclusion in this directory is not an endorsement.